Guggenheim Forecasts Strong Price Appreciation for Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics (NASDAQ:APGE) had its target price boosted by research analysts at Guggenheim from $130.00 to $160.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 103.74% from the stock’s previous close.

APGE has been the subject of several other reports. Stephens assumed coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 16th. They set an “overweight” rating and a $95.00 price objective for the company. UBS Group upgraded Apogee Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 7th. Truist Financial assumed coverage on Apogee Therapeutics in a research note on Tuesday, March 17th. They set a “hold” rating and a $83.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, January 21st. Finally, Stifel Nicolaus set a $133.00 price target on Apogee Therapeutics in a research note on Tuesday, January 6th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Apogee Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $110.43.

Apogee Therapeutics Stock Up 7.6%

Shares of NASDAQ:APGE opened at $78.53 on Tuesday. Apogee Therapeutics has a 52-week low of $26.20 and a 52-week high of $85.04. The stock has a market cap of $5.46 billion, a P/E ratio of -18.61 and a beta of 1.39. The business has a fifty day moving average of $71.09 and a two-hundred day moving average of $64.05.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.02. On average, equities analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current year.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00. Following the sale, the chief executive officer owned 1,152,987 shares of the company’s stock, valued at $86,220,367.86. The trade was a 1.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carl Dambkowski sold 18,700 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00. Following the transaction, the insider owned 212,523 shares in the company, valued at $16,542,790.32. This trade represents a 8.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 1,839,700 shares of company stock worth $140,118,083. 42.77% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Apogee Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Exane Asset Management purchased a new position in Apogee Therapeutics in the 3rd quarter valued at approximately $2,048,000. JPMorgan Chase & Co. increased its position in shares of Apogee Therapeutics by 57.9% during the third quarter. JPMorgan Chase & Co. now owns 1,137,731 shares of the company’s stock worth $45,202,000 after acquiring an additional 417,161 shares during the period. Rafferty Asset Management LLC raised its stake in shares of Apogee Therapeutics by 55.9% in the third quarter. Rafferty Asset Management LLC now owns 65,796 shares of the company’s stock valued at $2,614,000 after acquiring an additional 23,585 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Apogee Therapeutics in the third quarter valued at $1,986,000. Finally, SG Americas Securities LLC purchased a new position in Apogee Therapeutics in the third quarter valued at $5,333,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics News Roundup

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase II Part A results for zumilokibart showing sustained, durable responses and attractive infrequent dosing — data cited as boosting the drug’s commercial promise and near‑term clinical catalysts (Part B 16‑week induction data in Q2; potential Phase 3 in H2 2026). Zacks: APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
• Positive Sentiment: Investor enthusiasm reinforced by buy‑side commentary and bullish coverage calling APGE a “Strong Buy” ahead of upcoming readouts and potential Phase 3 start. Seeking Alpha highlights the program’s extended‑half‑life profile and upcoming catalysts. Seeking Alpha: Strong Buy
• Positive Sentiment: Several firms raised price targets and maintained buy ratings (Citigroup, Canaccord, Guggenheim), increasing upside estimates and supporting near‑term investor optimism. Benzinga: Analyst Coverage TickerReport: Guggenheim Raise
• Neutral Sentiment: Reported short‑interest data appears anomalous (entries showing 0 shares and NaN changes across multiple reports), so there’s no clear short‑pressure signal to explain price moves; treat the short‑interest items as unreliable until clarified.
• Negative Sentiment: Apogee priced an underwritten public offering of 5,000,000 shares at $70.00 (aggregate gross proceeds ~$350M) with a 30‑day option for up to 750,000 additional shares — this raises cash and extends runway but is dilutive and was priced below the current market, which can cap near‑term upside. Closing expected March 26, subject to conditions. GlobeNewswire: Offering Announcement MSN: Offering Coverage

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.